GSK and FDA Warn Against Nebulization of Relenza (zanamivir) Inhalation Powder

GSK and FDA Warn Against Nebulization of Relenza (zanamivir) Inhalation Powder
October 9, 2009
Audience: Infectious disease healthcare professionals, hospital risk managers.

GlaxoSmithKline (GSK) and FDA notified healthcare professionals of a
report of the death of a patient with influenza who received Relenza
(zanamivir) Inhalation Powder which was solubilized and administered
by mechanical ventilation. Relenza (zanamivir) Inhalation Powder is
not intended to be reconstituted in any liquid formulation and is not
recommended for use in any nebulizer or mechanical

--
esgdivisionmedica.4t.com

Comentarios

Entradas populares de este blog

cómo diseñar un hospital veterinario by @esgdm